A G240R amino acid replacement has been introduced into GlyRSUAS.Tag:HA.
G15096237M
G240R | GlyRS-PA; G326R | GlyRS-PB; G326R | GlyRS-PC
G326R
Analogous mutation in human GARS implicated in Charcot-Marie-Tooth disease, type 2D; mutation carried on in vitro construct; site of nucleotide substitution in fly gene inferred by FlyBase curator based on reported amino acid change.
Ubiquitous expression of Aats-glyG240R.Scer\UAS.T:Ivir\HA1 under the control of a strong Act5C driver (the P{Act5C-GAL4}25FO1 insertion of Scer\GAL4Act5C.PI) severely impairs fly development at the late pupal stage and yields only 3% escapers. No effect on viability is seen when Aats-glyG240R.Scer\UAS.T:Ivir\HA1 is expressed under the control of another insertion, P{Act5C-GAL4}17bFO1. Expression in the nervous system under the control of Scer\GAL4nSyb.PS has no effect on viability, but progressive climbing impairment is observed at days 20 and 30 compared to wild type.
Flies expressing Aats-glyG240R.Scer\UAS.T:Ivir\HA1 under the control of Scer\GAL4OK307 exhibit defects in the Giant Fibre-Trochanteral-Motoneuron-Tergotrochanteral Muscle (GF-TTMn-TTM) circuit. Upon GF stimulation, a mild but significant increase in response latencies is seen compared to controls. Following frequencies after a train of stimulations at 100 Hz are reduced compared to wild type.
Expression of Aats-glyG240R.Scer\UAS.T:Ivir\HA1 under the control of Scer\GAL4GMR.PU has no effect on ommatidial organisation.